The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Amgen’s KRAS inhibitor, Macrogenics’ breast cancer project and Roche’s entrectinib stand out as the curtain lifts on thousands of abstracts due to be presented at the…
The companies’ DS-8201 succeeds in breast cancer patients who had failed Kadcyla, and will go before the regulators later this year.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
UK group bets billions on an Her2 project slated for late-line patients and those with lower expression of the target protein.
Issues with manufacturing, not exactly a new problem for Immunomedics, derail the company’s bid for glory.
It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.
After years in the wilderness acute myeloid leukaemia is seeing a wave of activity, and there could be more targeted agents to come.